h3k27m peptide vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02960230)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- k27m
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04808245 | Phase 1 | Dec 6, 2021 | Deutsche Krebshilfe e.V., German Cancer Research Center, Humboldt University, Johannes Gutenburg University, Roche |
| NCT02960230 | Phase 1 | Nov 1, 2016 | University of California, San Francisco, V Foundation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Deutsche Krebshilfe e.V. | Academic/Hospital | 1 | 0 | 1 | 2021 |
| German Cancer Research Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Humboldt University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Johannes Gutenburg University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Roche | For profit | 1 | 0 | 1 | 2021 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2016 |
| V Foundation | Academic/Hospital | 1 | 0 | 1 | 2016 |
7 organizations
Page 1 / 1